Krsnaa Diagnostics Limited has informed the Exchange about change in Management
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krsnaa Diagnostics announced significant board changes at its April 17, 2026 meeting. The company appointed two new Independent Directors - Mr. Raju Venkatraman (a serial entrepreneur and former Chairman of Medall Healthcare) and Ms. Lilian Jessie Paul (marketing strategist and board member at PB Fintech), both for two-year terms effective April 25, 2026. Mr. Chetan Desai was reappointed as Independent Director for five years. The company also appointed Mr. Chandra Prakash Singh as Interim CFO with effect from April 17, 2026. Three directors - Ms. Pallavi Bhatevara (Whole-time Director) and Independent Directors Mr. Rajiva Ranjan Verma and Ms. Chhaya Palrecha - are stepping down upon completion of their tenures. All board committees have been reconstituted with the new directors assuming key roles including chairmanship positions.
These are routine board changes driven by director tenures expiring, with experienced replacements being appointed. The company appears to be proactively strengthening governance with industry veterans. No red flags from a governance perspective, though investors should note the CFO transition remains interim pending a permanent appointment.